VLX1570, known as an inhibitor of USP14 and UCHL5, is in the middle of a clinical trial (Phases 1 and 2) to confirm its stability and efficiency for the multiple myeloma (NCT02372240). The gene discussed is UCHL5; the disease is plasma cell myeloma.